Document Detail

Safety of iodinated intravenous contrast medium administration in sickle cell disease.
MedLine Citation:
PMID:  22195536     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Increased sickling of erythrocytes following intravenous iodinated contrast has been described in patients with sickle cell disease. In vitro, the effect is correlated with the tonicity, viscosity, acidity, and ionic nature of contrast media. Less erythrocyte sickling is observed in vitro with second-generation low- and iso-osmolar contrast agents. Clinical impact of these newer intravenous contrast agents has not been investigated.
PURPOSE: To review adverse outcomes following contrast administration in a cohort of patients with sickle cell disease.
METHODS: Inpatients with sickle cell disease who received iodinated intravenous were identified. Medical records were reviewed for evidence of worsening crisis and occurrence of adverse events within 48 hours of contrast administration. Data points were further analyzed with the goal of identifying predictors of adverse outcome.
RESULTS: There were 132 imaging studies that met inclusion criteria in 79 patients, mostly with homozygous hemoglobin S. The low-osmolar contrast Optiray (Coviden Imaging Inc., Hazelwood, Mo) was used in 45%. Administration of fluids, Mucomyst (Bristol-Myers Squibb, New York, NY), oxygen, or blood transfusion preceded 58% of studies. Minor adverse events followed 16% of studies, with new or worsening pain being most common (12%). Contrast-induced nephropathy occurred in 1.5%, resolving in all cases. Prehydration was associated with a decreased incidence of adverse events (P=.02).
CONCLUSION: Adverse events related to intravenous contrast occur in sickle cell disease patients at a rate similar to the general population, without an increase in contrast-induced nephropathy. Subjective reports of new or worsening pain crisis do not translate to objective findings. Beneficial diagnostic imaging can be performed without increased risk of serious complication in this population.
Kimberly L Campbell; Laryssa M Hud; Suzanne Adams; Jocelyn Andrel; Samir K Ballas; Arthur M Feldman; David Axelrod
Related Documents :
1154466 - Serum lipids and uric acid relationship in ischemic thrombotic cerebrovascular disease.
23666316 - Induction of response with etanercept-methotrexate therapy in patients with moderately ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of medicine     Volume:  125     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  100.e11-6     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Division of Cardiology, Thomas Jefferson University Hospital, Philadelphia, Pa.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial i...
Next Document:  Virulence of Newcastle disease virus: what is known so far?